share_log

Novo Integrated Sciences | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

Novo Integrated Sciences | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

Novo Integrated Sciences | NT 10-Q:季報延遲披露公告
美股SEC公告 ·  07/15 16:20

Moomoo AI 已提取核心訊息

Novo Integrated Sciences, Inc. has announced a delay in filing its Quarterly Report on Form 10-Q for the quarter ended May 31, 2024. The company cited the need for additional time to obtain and compile certain required information as the reason for the delay, stating that it could not be resolved without unreasonable effort and expense. Novo Integrated Sciences expects to file the report within the five-day extension period allowed by the SEC. The company confirmed that all other periodic reports have been filed as required, and there are no significant changes in results of operations from the corresponding period for the last fiscal year anticipated in the earnings statements to be included in the delayed report. The notification was signed by CEO Robert Mattacchione on July 15, 2024.
Novo Integrated Sciences, Inc. has announced a delay in filing its Quarterly Report on Form 10-Q for the quarter ended May 31, 2024. The company cited the need for additional time to obtain and compile certain required information as the reason for the delay, stating that it could not be resolved without unreasonable effort and expense. Novo Integrated Sciences expects to file the report within the five-day extension period allowed by the SEC. The company confirmed that all other periodic reports have been filed as required, and there are no significant changes in results of operations from the corresponding period for the last fiscal year anticipated in the earnings statements to be included in the delayed report. The notification was signed by CEO Robert Mattacchione on July 15, 2024.
Novo Integrated Sciences公司宣佈延遲提交2024年5月31日結束的第10-Q表格的季度報告。公司稱需要額外的時間來獲取和編譯某些必需的信息,這是延遲報告的原因,並稱該問題無法在沒有不合理的努力和費用的情況下解決。Novo Integrated Sciences預計在美國證券交易委員會允許的五天延期期間內提交報告。該公司確認所有其他週期性報告已按要求提交,並且預計在延遲報告中包括的盈利報告中,營運結果與去年相應時期無顯著變化。該通知由首席執行官羅伯特·馬塔基昂(Robert Mattacchione)於2024年7月15日簽署。
Novo Integrated Sciences公司宣佈延遲提交2024年5月31日結束的第10-Q表格的季度報告。公司稱需要額外的時間來獲取和編譯某些必需的信息,這是延遲報告的原因,並稱該問題無法在沒有不合理的努力和費用的情況下解決。Novo Integrated Sciences預計在美國證券交易委員會允許的五天延期期間內提交報告。該公司確認所有其他週期性報告已按要求提交,並且預計在延遲報告中包括的盈利報告中,營運結果與去年相應時期無顯著變化。該通知由首席執行官羅伯特·馬塔基昂(Robert Mattacchione)於2024年7月15日簽署。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息